General
Preferred name
CIPROFIBRATE
Synonyms
Ciprofibrate D6 ()
Win35833 ()
Win-35833 ()
WIN 35833 ()
NSC-759617 ()
Modalim ()
Ciprofibrate-d6 ()
P&D ID
PD001436
CAS
52214-84-3
2070015-05-1
Tags
natural product
drug
available
Approved by
MHRA
First approval
2009
Drug Status
investigational
approved
withdrawn
Drug indication
Hyperlipoproteinemia
Antihyperlipoproteinemic
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Ciprofibrate is a PPARĪ± agonist. (GtoPdb)
DESCRIPTION Peroxizome proliferator;specific ligand for the nuclear peroxisome proliferator-activated receptor alpha (PPARalpha) (LOPAC library)
Compound Sets
23
AdooQ Bioactive Compound Library
A11727
Cayman Chemical Bioactives
18515
33917
ChEMBL Approved Drugs
CHEMBL557555
ChEMBL Drugs
CHEMBL557555
DrugBank
DB09064
DrugBank Approved Drugs
DB09064
DrugCentral
658
DrugCentral Approved Drugs
658
DrugMAP
DMGC5DB
DrugMAP Approved Drugs
DMGC5DB
DrugMatrix
Guide to Pharmacology
3438
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL557555
MedChem Express Bioactive Compound Library
HY-B0664
NPC Screening Collection
NURSA ligand set
nursa/index.jsf?doi=10.1621%2FZF1ZNH8T48
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
ciprofibrate
TargetMol Bioactive Compound Library
T1264
The Spectrum Collection
Withdrawn 2.0
w195
External IDs
32
Properties
(calculated by RDKit )
Molecular Weight
288.03
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
1
cLogP
3.59
TPSA
46.53
Fraction CSP3
0.46
Chiral centers
1.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
PPAR-alpha
Target
PPAR
Pathway
Cell Cycle/DNA Damage
Metabolism
DNA Damage/DNA Repair
Vitamin D Related/Nuclear Receptor
ATC
C10AB08
Toxicity type
muscular
Therapeutic Class
Anticancer Agents
Source data